Experimental Models for Evaluating Enzyme Induction Potential of New Drug Candidates in Animals and Humans and a Strategy for Their Use

Advances in Pharmacology

Volumn 43, Issue C, 1997, Pages 205-229

  Thompson, Thomas N ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; DRUG INTERACTION; DRUG SCREENING; ENZYME INDUCTION; ENZYMOLOGY; HUMAN; LIVER; METHODOLOGY; PHARMACOLOGY; REVIEW; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; LIVER; PHARMACOLOGY;

EID: 0030627337     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60207-0     Document Type: Article

References (177)

1. Aarts E.M. Evidence for the function of D-glucaric acid as an indicator for drug induced enhanced metabolism through the glucuronic acid pathway in man. Biochem. Pharmacol. 14 (1964) 359-363
2. Aarts E.M. D-glucaric-acid excretion as a test for hepatic enzyme induction. Lancet 1 704 (1971) 859
3. Adams J.B., and Poulos A. Enzymatic synthesis of steroid sulphates. III. Isolation and properties of estrogen sulphotransferase of bovine adrenal glands. Biochim. Biophys. Acta 146 (1967) 493-508
4. Alderman C.P., and Hill C.L. Abnormal bone mineral metabolism after long-term anticonvulsant treatment. Ann. Pharmacother. 28 (1994) 47-48
5. Arlotto M.P., Greenway D.J., and Parkinson A. Purification of two isozymes of rat liver microsomal cytochrome P450 with testosterone 7;ga-hydroxylase activity. Arch. Biochem. Biophys. 270 (1989) 441-457
6. Bachmann K.A., and Jauregui L. Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo. Xenobiotica 23 3 (1993) 307-315
7. Backman J.T., Olkkola K.T., and Neuvonen P.J. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59 (1996) 7-13
8. Baker A.L., Kotake A.N., and Schoeller D.A. Clinical utility of breath tests for the assessment of hepatic function. Semin. Liver Dis. 3 4 (1983) 318-329
9. Balian J.D., Sukhova N., Harris J.W., Hewett J., Pickle L., Goldstein J.A., Woosley R.L., and Flockhart D.A. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: A population study. Clin. Pharmacol. Ther. 56 6 (1995) 662-669
10. Bammel A., van der Mee K., Ohnhaus E.E., and Kirch W. Divergent effects of different enzyme-inducing agents on endogenous and exogenous testosterone. Eur. J. Clin. Pharmacol. 42 (1992) 641-644
11. Barry M., and Freely J. Enzyme induction and inhibition. Pharmacol. Ther. 48 (1990) 71-94
12. Barter R.A., and Klaassen C.D. Reduction of thyroid hormone levels and alteration of thyroid function by four representative UDP-glucuronosyltransferase inducers in rats. Toxicol. Appl. Pharmacol. 128 (1994) 9-17
13. Batt A.M., Siest G., Magdalou J., and Galteau M.M. Enzyme induction by drugs and toxins. Clin. Chim. Acta 209 (1992) 109-121
14. Benedetti M.S., and Dostert P. Induction and autoinduction properties of rifamycin derivatives: A review of animal and human studies. Environ. Health Perspect. 102 9 (1994) 101-105
15. Bernus I., Dickinson R.G., Hooper W.D., and Eadie M.J. Early stage autoinduction of carbamazepine metabolism in humans. Eur. J. Clin. Pharmacol. 47 (1994) 355-360
16. Bhagwat S.V., Boyd M.R., and Ravindranath V. Brain mitochondrial cytochromes P450: Xenobiotic metabolism, presence of multiple forms and their selective inducibility. Arch. Biochem. Biophys. 320 1 (1995) 73-83
17. Bienvenu T., Rey E., Pons G., D'Athis P., and Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 29 (1991) 441-445
18. Bock K.W., Frohling W., Remmer H., and Rexer B. Effects of phenobarbital and 3-methylcholanthrene on substrate specificity of rat liver microsomal UDP-glucuronyltransferase. Biochim. Biophys. Acta 327 (1973) 46-56
19. Bock K.W., Brunner G., Hoensch H., Huber E., and Josting D. Determination of microsomal UDP-glucuronyl-transferase in needle-biopsy specimens of human liver. Eur. J. Clin. Pharmacol. 14 (1978) 367-373
20. Bock K.W., Lipp H.P., and Bock-Hennig B.S. Induction of drug-metabolizing enzymes by xenobiotics. Xenobiotica 20 (1990) 1101-1111
21. Boddy A.V., Cole M., Pearson A.D.J., and Idle J.R. The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion. Cancer Chemother. Pharmacol. 36 (1995) 53-60
22. Bourdi M., Gautier J.C., Mircheva J., Larrey D., Guillouzo A., Andre C., Belloc C., and Beaune P.H. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: Specificity of autoantibodies and inductive capacity of the drug. Mol. Pharmacol. 42 (1992) 280-285
23. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
24. Breckenridge A. Enzyme induction in humans-clinical aspects-an overview. Pharmacol. Ther. 33 (1987) 95-99
25. Bresnick E., Foldes R., and Hines R.N. Induction of cytochrome P450 by xenobiotics. Pharmacol. Rev. 36 2 (1984) 43S-51S
26. Brockmöller J., and Roots I. Assessment of liver metabolic function-clinical implications. Clin. Pharmacokinet. 27 3 (1994) 216-248
27. Buchthal J., Grund K.E., Buchmann A., Schrenk D., Beaune P., and Bock K.W. Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa. Eur. J. Clin. Pharmacol. 47 (1995) 431-435
28. Bullock P., Pearce R., Draper A., Podval J., Bracken W., Veltman J., Thomas P., and Parkinson A. Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos. 23 7 (1995) 736-748
29. Burke M.D., and Mayer R.T. Ethoxyresorufin: Direct fluorometric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab. Dispos. 2 (1974) 583-588
30. Burke M.D., Thompson S., Weaver R.J., Wolf C.R., and Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin o-dealkylation in human and rat liver. Biochem. Pharmacol. 48 5 (1994) 923-936
31. Bush E.D., Low L.K., and Trager W.F. A sensitive and specific stable isotope assy for warfarin and its metabolites. Biomed. Mass Spectrom. 10 7 (1983) 395-398
32. Castle M.C. Glucuronidation of digitalis glycosides by rat liver microsomes: Stimulation by spironolactone and pregnenolone-16;ga-carbonitrile. Biochem. Pharmacol. 29 (1980) 1497-1502
33. Chen L.J., Bolt R.J., and Admirand W.H. Enzymatic sulfation of bile salts. Partial purification and characterization of an enzyme from rat liver that catalyzes the sulfation of bile salts. Biochim. Biophys. Acta 480 (1977) 219-227
34. Conney A.H. Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev. 19 3 (1967) 317-366
35. Diaz D., Fabre I., Daujat M., Saint Aubert B., Bories P., Michel H., and Maurel P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 99 (1990) 737-747
36. Dragnev K.H., Nims R.W., Fox S.D., Lindahl R., and Lubet R.A. Relative potencies of induction of hepatic drug-metabolizing enzyme genes by individual PCB congeners. Toxicol. Appl. Pharmacol. 132 2 (1995) 334-342
37. Dunn T.J., Lindahl R., and Pitot H.C. Differential gene expression in response to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). Noncoordinate regulation of a TCDD-induced aldehyde dehydrogenase and cytochrome P-450c in the rat. J. Biol. Chem. 263 22 (1988) 10878-10886
38. Durand D., Hampden C., Boobis A.R., Park B.K., and Davies D.S. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br. J. Clin. Pharmacol. 21 (1986) 1-7
39. Dutton D.R., and Parkinson A. Reduction of 7-alkoxyresorufins by NADPH-cytochrome P450 reductase and its differential effects on their O-dealkylation by rat liver microsomal cytochrome P450. Arch. Biochem. Biophys. 268 (1989) 617-629
40. Engel G., Hofmann U., Heidemann H., Cosme J., and Eichelbaum M. Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin. Pharmacol. Ther. 59 (1996) 613-623
41. Farrell G.C., and Murray M. Human cytochrome P450 Isoforms-their genetic heterogeneity and induction by omeprazole. Gastroenterology 99 (1990) 885-889
42. Fazio A. Oral contraceptive drug interactions: Important considerations (see comments) (review). South. Med. J. 84 8 (1991) 997-1002
43. Fleishaker J.C., Pearson L.K., and Peters G.R. Phenytoin causes a rapid increase in 6;gb-hydroxycortisol urinary excretion in humans-a putative measure of CYP3A induction. J. Pharm. Sci. 84 3 (1995) 292-294
44. Franceschini G., D'Werba J.P., Acquarica A.L., Gianfranceshi G., Michelagnoli S., and Sirtori C.R. Microsomal enzyme inducers raise plasma high-density lipoprotein cholesterol levels in healthy control subjects but not in patients with primary hypoalphalipoproteinemia. Clin. Pharmacol. Ther. 57 (1995) 434-440
45. Fry J.R., Garle M.J., and Lal K. Differentiation of cytochrome P-450 inducers on the basis of 7-alkoxycoumarin O-dealkylase activities. Xenobiotica 22 2 (1992) 211-215
46. Ged C., Rouillon J.M., Pichard L., Combalbert J., Bressot N., Bories P., Michel H., Beaune P., and Maurel P. The increase in urinary excretion of 6;gb-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br. J. Clin. Pharmacol. 28 (1989) 373-387
47. Gibaldi M. Induction of drug-metabolizing enzymes. Perspect. Clin. Pharm. 9 6 (1991) 41-46
48. Gleizes C., Eeckhoutte C., Pineau T., Alvinerie M., and Galtier P. Inducing effect of oxfendazole on cytochrome P4501A2 in rabbit liver. Consequences on cytochrome P450 dependent monooxygenases. Biochem. Pharmacol. 41 12 (1991) 1813-1820
49. Glowinski I.B., Radtke H.E., and Weber W.W. Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol. Pharmacol. 14 (1978) 940-949
50. Goldberg D.M. The expanding role of microsomal enzyme induction, and its implications for clinical chemistry. Clin. Chem. 26 6 (1980) 691-699
51. Gonzalez F.J., and Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 26 1&2 (1994) 165-183
52. Liu Gonzalez F.J., and Yano S.Y.M. Regulation of cytochrome P450 genes: Molecular mechanisms. Pharmacogenetics 3 (1993) 51-57
53. Grange J.M., Winstanley P.A., and Davies P.D.O. Clinically significant drug interactions with antituberculosis agents. Drug Saf. 11 4 (1994) 242-251
54. Grasso P., Sharratt M., and Cohen A.J. Role of persistent, non-genotoxic tissue damage in rodent cancer and relevance to humans. Annu. Rev. Pharmacol. Toxicol. 31 (1991) 253-287
55. Griffin R.J., Burka L.T., and Cunningham M.L. Activity of hepatic drug metabolizing enzymes following oxazepam-dosed feed treatment in B6C3F1 mice. Toxicol. Lett. 76 (1995) 251-256
56. Guengerich F.P., Wang P., and Davidson N.K. Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 21 (1982) 1698-1706
57. Habig W.H., Pabst M.J., and Jakoby W.B. Glutathione transferases: The first step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
58. Hearse D.J., and Weber W.W. Multiple N-acetyltransferases and drug metabolism, tissue distribution, characterization and significance of mammalian N-acetyltransferase. Biochem. J. 132 (1973) 519-526
59. Heymann E. Carboxylesterases and amidases. In: Jakoby W.B. (Ed). "Enzymatic Basis of Detoxication" 2 (1980), Academic Press, New York 291-323
60. Hietanen E., Laitinen M., and Koivusaari U. Effect of administration route of 3-methylcholanthrene on the inducibility of intestinal drug-metabolizing enzymes. Enzyme 25 (1980) 153-157
61. Hill R.N., Erdreich L.S., Paynter O.E., Roberts P.A., Rosenthal S.L., and Wilkinson C.F. Thyroid follicular cell carcinogenesis. Fundam. Appl. Toxicol. 12 4 (1989) 629-697
62. Hosokawa M., Maki T., and Satoh T. Multiplicity and regulation of hepatic microsomal carboxylesterases in rats. Mol. Pharmacol. 31 (1987) 579-584
63. Hosokawa M., Maki T., and Satoh T. Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans. Arch. Biochem. Biophys. 277 (1990) 219-227
64. Hosokawa M., Hirata K., Nakata F., Suga T., and Satoh T. Species differences in the induction of hepatic microsomal carboxylesterases caused by dietary exposure to di(2-ethlhexyl)phthalate, a peroxisome proliferator. Drug Metab. Dispos. 22 6 (1994) 889-894
65. Howard M.O., Schwartz L.W., Newton J.F., Qualls C.W., Yodis L.A.P., and Ventre J.R. Comparative biochemical and morphometric changes associated with induction of the hepatic mixed function oxidase system in the rat. Toxicol. Pathol. 19 2 (1991) 115-122
66. Hoyle V.R., Gilbert P.J., Troke J.A., Vose C.W., and Nicholson J.K. Studies on the biochemical effects of the aldose reductase inhibitor 2, 7-difluorospirofluorene- 9, 5′-imidazolidine-2′, 4′-dione (A1 1576, HOE 843). Detection of D-glucaric and D-glucuronic acid excretion by high resolution 1H and 13C NMR spectroscopy. Biochem. Pharmacol. 44 2 (1992) 231-241
67. Hunter J., Maxwell J.D., Carrella M., Stewart D.A., and Williams R. Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet 1 699 (1971) 572-575
68. Imaoka S., Inoue K., and Funae Y. Aminopyrine metabolism by multiple forms of cytochrome P-450 from rat liver microsomes: Simultaneous quantitation of four aminopyrine metabolites by high-performance liquid chromatography. Arch. Biochem. Biophys. 265 1 (1988) 159-170
69. Inoue S., Inokuma M., Harada T., Shibutani Y., Yoshitake T., Charles B., Ishida J., and Yamaguchi M. Simultaneous high performance liquid chromatographic determination of 6β-hydroxycortisol and cortisol in urine with fluorescence detection and its application for estimating hepatic drug-metabolizing enzyme induction. J. Chromatogr. B: Biomed. Appl. 661 (1994) 15-23
70. Ioannides C., and Parke D.V. Commentary: The cytochromes P-448-a unique family of enzymes involved in chemical toxicity and carcinogenesis. Biochem. Pharmacol. 36 24 (1987) 4197-4207
71. Ioannides C., and Parke D.V. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metab. Rev. 25 4 (1993) 485-501
72. Isojärvi J.I.T., Pakarinen A.J., Rautio A., Pelkonen O., and Myllylä V.V. Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia 35 6 (1994) 1217-1220
73. Iversen P.L., and Franklin M.R. Microsomal cytochrome P-450 "handprints": Five fractions from anion-exchange high-pressure liquid chromatography provide a rapid preliminary screen for selectivity in the induction and destruction of rat hepatic cytochrome P-450 subpopulations. Toxicol. Appl. Pharmacol. 78 (1985) 1-9
74. Jacolot F., Simon I., Dreano Y., Beaune P., Riche C., and Berthou F. Identification of the cytochrome P-450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol. 41 (1991) 1911-1919
75. Jones C.R., Guengerich F.P., Rice J.M., and Lubet R.A. Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. Pharmacogenetics 2 (1992) 160-172
76. Kalow W., and Tang B.K. Caffeine as a metabolic probe: Exploration of the enzymeinducing effect of cigarette smoking. Clin. Pharmacol. Ther. 49 (1991) 44-48
77. Kawajiri K., and Fujii-Kurijama Y. P450 and human cancer. Jpn. J. Cancer Res. 82 (1991) 1325-1335
78. Kharasch E.D., Thummel K.E., Mhyre J., and Lillibridge J.H. Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin. Pharmacol. Ther. 53 6 (1993) 643-650
79. Kocarek T.A., Schuetz E.G., Strom S.C., Fisher R.A., and Guzelian P.S. Comparative analysis of cytochrome P4503A induction in primary cultures of rat, rabbit, and human hepatocytes. Drug Metab. Dispos. 23 3 (1995) 415-421
80. Koop D.R. Hydroxylation of para-nitrophenol by rabbit ethanol inducible cytochrome P-450 isozyme 3A. Mol. Pharmacol. 29 (1986) 399-404
81. Kostrubsky V.E., Strom S.C., Wood S.G., Wrighton S.A., Sinclair P.R., and Sinclair J.F. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch. Biochem. Biophys. 322 (1995) 516-520
82. Kotake A.N., Schoeller D.A., Lambert G.H., Baker A.L., Schaffer D.D., and Josephs H. The caffeine CO2 breath test: Dose response and route of N-demethylation in smokers and nonsmokers. Clin. Pharmacol. Ther. 32 2 (1982) 261-269
83. Kreamer B.L., Staecker J.L., Sawada N., Sattler G.L., Hsia M.T.S., and Pitot H.C. Use of a low-speed iso-density Percoll centrifugation method to increase the viability of isolated hepatocyte preparations. In Vitro 22 (1986) 201
84. Kudriakova T.B., Sirota L.A., Rozova G.I., and Gorkov V.A. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br. J. Clin. Pharmacol. 33 (1992) 611-615
85. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 227 (1970) 680-685
86. Lake B.G., Beamand J.A., Japenga A.C., Renwick A., Davies S., and Price R.J. Induction of cytochrome P-450-dependent enzyme activities in cultured rat liver slices. Food Chem. Toxicol. 31 5 (1993) 377-386
87. Lan S.J., Weinstein S.H., Keim G.R., and Migdalof B.H. Induction of hepatic drug-metabolizing enzymes in rats, dogs, and monkeys after repeated administration of an anti-inflammatory hexahydroindazole. Xenobiotica 13 6 (1983) 329-335
88. Lane E.A., and Parashos I. Drug pharmacokinetics and the carbon dioxide breath test. J. Pharmacokinet. Biopharm. 14 1 (1986) 29-49
89. Li A.P., Roque M.A., Beck D.J., and Kaminski D.L. Isolation and culturing of hepatocytes from human liver. J. Tissue Cult, Methods 14 (1992) 139-146
90. Li A.P., Rasmussen A., Xu L., and Kaminiski D.L. Rifampincin induction of lidocaine metabolism in cultured human hepatocytes. J. Pharmacol. Exp. Ther. 274 (1995) 673-677
91. Li A.P., Kaminski D.L., and Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 104 (1995) 1-8
92. Lown K.S., Thummel K.E., Benedict P.E., Shen D.D., Turgeon D.K., Berent S., and Watkins P.B. Pharmacokinetics and drug disposition. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther. 57 (1995) 16-24
93. Lowry O.H., Rosebrough J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
94. Lubet R.A., Mayer R.T., Cameron J.W., Nims R.W., Burke M.D., Wolff T., and Guengerich F.P. Dealkylation of pentoxyresorufin: A rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238 1 (1985) 43-48
95. Lubet R.A., Nims R.W., Ward J.M., Rice J.M., and Diwan B.A. Induction of cytochrome P450b and its relationship to liver tumor promotion. J. Am. Coll. Toxicol. 8 2 (1989) 259-268
96. Luoma P.V. Microsomal enzyme induction, lipoproteins and atherosclerosis. Pharmacol. Toxicol. 62 (1988) 243-249
97. Maekubo H., Ozaki S., Mitmaker B., and Kalant N. Preparation of human hepatocytes from primary culture. In Vitro 18 (1982) 483-491
98. Mahnke A., Roos P.H., Hanstein W.G., and Chabot G.G. In vivo induction of cytochrome P450 CYP3A expression in rat leukocytes using various inducers. Biochem. Pharmacol. 51 (1996) 1579-1582
99. Mazel P. Experiments illustrating drug metabolism in vitro. In: LaDu B.N., Mandel H.G., and Way E.L. (Eds). "Fundamentals of Drug Metabolism and Disposition" (1971), Williams & Wilkins, Baltimore 546-550
100. McInnes G.T., and Brodie M.J. Drug interactions that matter. A critical reappraisal. Drugs 36 (1988) 83-110
101. McKillop D. Effects of phenobarbitone and β-naphthoflavone on hepatic microsomal drug metabolising enzymes of the male beagle dog. Biochem. Pharmacol. 34 17 (1985) 3137-3142
102. McLean A.E.M. Is enzyme induction good for you? A problem of epidemiology and toxicology. Hum. Toxicol. 7 (1988) 419-422
103. Morel F., Beaune P.H., Ratanasavanh D., Flinois J.P., and Yang C.S. Expression of cytochrome P-450 enzymes in cultured human hepatocytes. Eur. J. Biochem. 191 2 (1990) 437-444
104. Nash T. The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. J. Biol. Chem. 55 (1953) 416-421
105. Nebert D.W. Multiple forms of inducible drug-metabolizing enzymes: A reasonable mechanism by which any organism can cope with adversity. Mol. Cell. Biochem. 27 1 (1979) 27-46
106. Nedelcheva V., and Gut I. P450 in the rat and man: Methods of investigation, substrate specificities and relevance to cancer. Xenobiotica 24 12 (1994) 1151-1175
107. Nicolas F., De Sousa G., Thomas P., Placidi M., Lorenzon G., and Rahmani R. Comparative metabolism of 3′-azido-3′-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans. Drug Metab. Dispos. 23 3 (1995) 308-313
108. Nims R.W., Beebe L.E., Dragnev K.H., Thomas P.E., Fox S.D., Issaq H.J., Jones C.R., and Lubet R.A. Induction of hepatic CYP1A in male F344/NCr rats by dietary exposure to Aroclor 1254: Examination of immunochemical, RNA, catalytic, and pharmacokinetic endpoints. Environ. Res. 59 2 (1992) 447-466
109. Oesch F., Jerina D.M., and Daly J. A radiometric assay for hepatic epoxide hydrase activity with {7-3H}styrene oxide. Biochim. Biophys. Acta 227 (1971) 685-691
110. Ohnhaus E.E., and Park B.K. Measurement of urinary 6-;gb-hydroxycortisol excretion as an in vivo parameter in the clinical assessment of the microsomal enzyme-inducing capacity of antipyrine, phenobarbitone and rifampicin. Eur. J. Pharmacol. 15 2 (1979) 139-145
111. Okey A.B. Enzyme induction in the cytochrome P-450 system. Pharmacol. Ther. 45 (1990) 241-298
112. Okey A.B., Roberts E.A., Harper P.A., and Denison M.S. Induction of drugmetabolising enzymes: Mechanisms and consequences. Clin. Biochem. 19 (1986) 132-141
113. Omiecinski C.J., Redlich C.A., and Costa P. Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: Detection by the polymerase chain reaction. Cancer Res. 50 (1990) 4315-4321
114. Omura T., and Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 239 7 (1964) 2370-2378
115. Orlando R., Benvenuti C., Mazzo M., and Palatini P. The pharmacokinetics of teniloxazine in healthy subjects and patients with hepatic cirrhosis. Br. J. Clin. Pharmacol. 39 4 (1995) 445-448
116. Paolini M., Biagi G.L., Bauer C., and Cantelli-Forti G. On the nature of nongenotoxic carcinogens. A unified theory including NGCs, co-carcinogens and promotors. Mutat. Res. 281 4 (1992) 245-246
117. Park B.K., and Breckenridge A.M. Clinical implications of enzyme induction and enzyme inhibition. Clin. Pharmacokinet. 6 (1981) 1-24
118. Parke D.V., Ioannides C., and Lewis D.F.V. The role of the cytochromes P450 in the detoxication and activation of drugs and other chemicals. Can. J. Physiol. Pharmacol. 69 (1991) 537-549
119. Parkinson A. Biotransformation of xenobiotics. In: Klaasen C.D. (Ed). "Casarett & Doull's Toxicology, The Basic Science of Poisons". 5th ed. (1946), McGraw-Hill, New York 113-156
120. Parkinson A., and Hurwitz A. Omeprazole and the induction of human cytochrome P-450: A response to concerns about potential adverse effects. Gastroenterology 100 4 (1991) 1157-1164
121. Partovian C., Jacqz-Aigrain E., Keundjian A., Jaillon P., and Funck-Brentano C. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans. Clin. Pharmacol. Ther. 58 3 (1995) 257-263
122. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs. Pharmacol. Ther. 33 (1987) 139-144
123. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., and Yang C.S. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3 6 (1990) 566-573
124. Peter R., Bocker R., Beaune P.H., Iwasaki M., Guengerich F.P., and Yang C.S. Chem. Res. Toxicol. 4 3 (1991) 389
125. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., and Maurel P. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18 5 (1990) 595-606
126. Pohl R., and Fouts J.R. A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal. Biochem. 107 (1980) 150-155
127. Poland A. Induction of the drug-metabolizing enzymes (review). IARC Sci. Publ. 39 (1982) 351-364
128. Poland A., and Kappas A. The metabolism of aminopyrine in chick embryo hepatic cell culture: Effects of competitive substrates and carbon monoxide. Mol. Pharmacol. 7 6 (1971) 697-705
129. Porter W.R., Wheeler C., and Trager W.F. Changes in the metabolic profiles of R-and S-warfarin and R- and S-phenprocoumon as a probe to categorize the effect of inducing agents on microsomal hydroxylases. Biochem. Pharmacol. 30 22 (1981) 3099-3104
130. Rao G.S., Haueter G., Rao M.L., and Breuer H. An improved assay for steroid glucuronyltransferase in rat liver microsomes. Anal. Biochem. 74 (1976) 35-40
131. Remmer H. Induction and its influence on human cancer. Pharmacol. Ther. 33 (1987) 89-94
132. Rice J.M., Diwan B.A., Hu H., Ward J.M., Nims R.W., and Lubet R.A. Enhancement of hepatocarcinogenesis and induction of specific cytochrome P450-dependent monooxygenase activities by the barbiturates allobarbital, aprobarbital, pentobarbital, secobarbital and 5-phenyl- and 5-ethylbarbituric acids. Carcinogenesis (London) 15 2 (1994) 395-402
133. Rodrigues A.D. Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem. Pharmacol 48 12 (1994) 2147-2156
134. Romano M.C., Straub K.M., Yodis Y.A.D., Eckardt R.D., and Newton J.F. Determination of microsomal lauric acid hydroxylase activity by HPLC with flow-through radiochemical quantitation. Anal. Biochem. 170 (1988) 83-93
135. Rost K., Brösicke H., Scheffler M., and Roots I. Dose dependent induction of CYP1A2 activity by omeprazole (Antra). Int. J. Clin. Pharmacol. Ther. Toxicol. 30 11 (1992) 542-543
136. Rost K.L., Brösicke H., Heinemeyer G., and Roots I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 20 (1994) 1204-1212
137. Ryan D.E., and Levin W. Purification and characterization of hepatic microsomal cytochrome P-450. Pharmacol. Ther. 45 (1990) 153-239
138. Ryan D.E., Thomas P.E., Korzeniowski D., and Levin W. Separation and characterization of highly purified forms of liver microsomal cytochrome P-450 from rats treated with polychlorinated biphenyls, phenobarbital, and 3-methylcholanthrene. J. Biol. Chem. 254 (1979) 1365-1374
139. Ryan D.E., Thomas P.E., and Levin W. Hepatic microsomal cytochrome P-450 form rats treated with isosafrole. J. Biol. Chem. 255 (1980) 7941-7955
140. Sandstad O., Osnes T., Skar V., and Osnes M. Urinary D-glucaric acid, a marker substance for microsomal enzyme induction. Methodological aspects, responses to alcohol and findings in workers exposed to toluene. Scand. J. Clin. Lab. Invest. 53 (1993) 327-333
141. Schrenzel J., Dayer P., Leemann T., Weidekamm E., Portmann R., and Lew D.P. Influence of rifampin on fleroxacin pharmacokinetics. Antimicrob. Agents Chemother. 37 10 (1993) 2132-2138
142. Sekura R.D., and Jakoby W.B. Phenol sulfotransferases. J. Biol. Chem. 254 (1979) 5658-5663
143. Sekura R.D., Marcus C.J., Lyon E.S., and Jakoby W.B. Assay of sulfotransferases. Anal. Biochem. 95 (1979) 82-86
144. Shaw I.C., and Jones H.B. Mechanisms of non-genotoxic carcinogenesis. Trends Pharmacol. Sci. 15 (1994) 89-93
145. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270 1 (1994) 414-423
146. Siest G., Batt A.M., Fournel-Gigleux S., Galteau M.M., Wellman-Bednawska M., Minn A., and Costesec A.A. Induction of plasma and tissue enzymes by drugs: Significance in toxicological studies. Xenobiotica 18 Suppl. 1 (1988) 21-34
147. Skett P., and Bayliss M. Time for a consistent approach to preparing and culturing hepatocytes. Xenobiotica 26 1 (1996) 1-7
148. Snyder R., and Remmer H. Classes of hepatic microsomal mixed function oxidase inducers. Pharmacol. Ther. 7 (1979) 203-244
149. Sonderfan A.J., Arlotto M.P., Dutton D.R., McMillen S.M., and Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch. Biochem. Biophys. 255 (1987) 27-41
150. Soucek P., and Gut I. Cytochromes P-450 in rats: Structures, functions, properties and relevant human forms (review). Xenobiotica 22 1 (1992) 83-103
151. Stanley L.A., Carmichael J., and Wolf C.R. Cytochrome P-450 induction in human lung tumor-derived cell lines. Characterization and effect of inflammatory mediators. Eur. J. Biochem. 208 (1992) 521-529
152. Stegeman J.J., Hahn M.E., Weisbrod R., Woodin B.R., Joy J.S., Najibi S., and Cohen R.A. Induction of cytochrome P4501A1 by aryl hydrocarbon receptor agonists in porcine aorta endothelial cells in culture and cytochrome P4501A1 activity in intact cells. Mol. Pharmacol. 47 (1995) 296-306
153. Swinney D.C., Webb A.S., and Freedman R. A novel rat hepatic clofibrate-inducible cytochrome P450 that is not a lauric acid hydroxylase. Biochem. Pharmacol. 42 12 (1991) 2341-2349
154. Takacs A.R. Ancillary approaches to toxicokinetic evaluations. Toxicol. Pathol. 23 2 (1995) 179-186
155. Talalay P., Fahey J.W., Holtzclaw W.D., Prestera T., and Zhang Y. Chemoprotection against cancer by Phase 2 enzyme induction. Toxicol. Lett. 82/83 (1995) 173-179
156. Tassaneeyakul W., Veronese M.E., Birkett D.J., Doecke C.J., McManus M.E., Sansom L.N., and Miners J.O. Co-regulation of phenytoin and tolbutamide metabolism in humans. Br. J. Clin. Pharmacol. 34 6 (1992) 494-498
157. Thomas P.E., Reik L.M., Ryan D.E., and Levin W. Characterization of nine monoclonal antibodies against rat hepatic cytochrome P-450c. J. Biol. Chem. 259 (1984) 3890-3899
158. Thompson T.N., Watkins J.B., Gregus Z., and Klaassen C.D. Effect of microsomal enzyme inducers on the soluble enzymes of hepatic phase II biotransformation. Toxicol. Appl. Pharmacol. 66 (1982) 400-408
159. T.N. Thompson J.G. Geary S.E. Unwin J.J. Dunn P.W. Brown D.R. Osborne K.K. Hwang 1990). Evaluation of ML 1012 as an hepatic enzyme inducer in rats, dogs, and monkeys. Abstr., North Am. International Society for the Study of Xenobiotics (ISSX) Meet., 3rd, San Diego, Ca, 1990, Abstr. No. 185
160. Thummel K.E., Shen D.D., Podall T.D., Kunze K.L., Trager W.F., Hartwell P.S., Raisys V.A., Marsh C.L., McVicor J.P., Barr D.M., Perkins J.D., and Carithers Jr. R.L. Use of midazolam as a human cytochrome P450 3A probe: I. In vitroin vivo correlations in liver transplant patients. J. Pharmacol. Exp. Ther. 271 1 (1994) 549-556
161. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. U. S. A. 76 (1979) 4350-4354
162. J.E. Turner J.H. Leighton M. Cunningham S.L. Cox L.B. Hogan M.J. O'Sullivan 1994). The development of enzyme linked immunoadsorbent assays (ELISA's) for cytochrome P450's. Abstr. North Am. ISSX Meet., 6th, Raleigh, NC, 1994, Abstr. No. 180
163. Van Iersel M.L., Henderson P.S.C.I., Walters D.G., Price R.J., Wolf C.R., and Lake B.G. Metabolism of [3- 14C] coumarin by human liver microsomes. Xenobiotica 24 8 (1994) 795-803
164. VanRoy F.P., and Heirwegh K.P.M. Determination of bilirubin glucuronide and assay of glucuronyltransferase with bilirubin as acceptor. Biochem. J. 107 (1968) 507-518
165. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin. Pharmacokinet. 22 1 (1992) 47-65
166. Waechter F., Bieri F., Staubli W., and Bentley P. Induction of cytosolic and microsomal epoxide hydrolases by the hypolipidaemic compound nafenopin in the mouse liver. Biochem. Pharmacol. 33 1 (1984) 31-34
167. Waechter F., Bentley P., Bieri F., Muakkassah-Kelly S., Staubli W., and Villermain M. Organ distribution of epoxide hydrolases in cytosolic and microsomal fractions of normal and nafenopin-treated male DBA/2 mice. Biochem. Pharmacol. 37 20 (1988) 3897-3903
168. Watkins J.B., and Klaassen C.D. Effect of inducers and inhibitors of glucuronidation on the biliary excretion and choleretic action of valproic acid in the rat. J. Pharmacol. Exp. Ther. 220 (1982) 305-310
169. Watkins J.B., Gregus Z., Thompson T.N., and Klaassen C.D. Induction studies on the functional heterogeneity of rat liver UDP-glucuronosyltransferases. Toxicol. Appl. Pharmacol. 64 (1982) 439-446
170. Watkins P.B. Role of cytochromes P450 in drug metabolism and hepatoxicity. Semin. Liver Dis. 10 4 (1990) 235-250
171. Watkins P.B., Hamilton R.A., Annesley T.M., Ellis C.N., Kolars J.C., and Voorhees J.J. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther. 48 (1990) 120-129
172. Watkins P.B., Turgeon D.K., Saenger P., Lown K.S., Kolars J.C., Hamilton T., Fishman K., Guzelian P.S., and Voorhees J.J. Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin. Pharmacol. Ther. 52 (1992) 265-273
173. Waxman D.J., and Azaroff L. Phenobarbital induction of cytochrome P-450 gene expression. Biochem. J. 281 (1992) 577-592
174. Weber W.W. N-acetyltransferase (mammalian liver). In: Tabor H., and Tabor C.W. (Eds). "Methods in Enzymology" 17B (1971), Academic Press, New York 805-811
175. Williams J.B., Lu A.Y., Cameron R.G., and Pickett C.B. Rat liver NAD(P)H: quinone reductase. Construction of a quinone reductase cDNA clone and regulation of quinone reductase mRNA by 3-methylcholanthrene and in persistent hepatocyte nodules induced by chemical carcinogens. J. Biol. Chem. 261 12 (1986) 5524-5528
176. Winsnes A. Studies on the activation in vitro of glucuronyltransferase. Biochim. Biophys. Acta 191 (1969) 279-291
177. Young W.S., and Lietman P.S. Chloramphenicol glucuronyltransferase: Assay, ontogeny, and inducibility. J. Pharmacol. Exp. Ther. 204 (1978) 203-211